Literature DB >> 26370301

The updated incidences and mortalities of major cancers in China, 2011.

Wanqing Chen1, Rongshou Zheng2, Hongmei Zeng3, Siwei Zhang4.   

Abstract

INTRODUCTION: The National Central Cancer Registry (NCCR) of China collected population-based cancer registration data from all cancer registries in China. This study aimed to compile national cancer incidences and mortalities in 2011 and estimate cancer incident new cases and cancer deaths.
METHODS: In 2014, there were 234 cancer registries that submitted records of new cancer cases and cancer deaths that occurred in 2011 to the NCCR. All datasets were evaluated based on the criteria of data quality of the NCCR. The data of 177 registries was of sufficient quality and was compiled to evaluate cancer statistics in 2011. The pooled data were stratified by area, sex, age group, and cancer type. Cancer incident cases and deaths were estimated using age-standardized rates (ASR) and the Chinese population. All incidences and mortalities were age-standardized to the 2000 Chinese standard population and Segi's population.
RESULTS: The estimates of new cancer incident cases and cancer deaths were 3,372,175 and 2,113,048 in 2011, respectively. The crude incidence was 250.28/1,00,000 (277.77/1,00,000 for males and 221.37/1,00,000 for females). The ASRs of incidence by the Chinese standard population (ASRIC) and by the world standard population (ASRIW) were 186.34/1,00,000 and 182.76/1,00,000, respectively, with a cumulative incidence (0-74 years old) of 21.20%. Cancers of the lung, female breast, stomach, liver, colorectum, esophagus, cervix, uterus, prostate, and ovary were the most common cancers, accounting for approximately 75% of all new cancer cases. Lung, liver, gastric, esophageal, colorectal, female breast, pancreatic, brain, and cervical cancers and leukemia were the leading causes of cancer death, accounting for approximately 80% of all cancer deaths. Cancer incidence, mortality, and spectrum were all different between urban and rural areas and between males and females.
CONCLUSIONS: The population covered by the cancer registries greatly increased from 2010 to 2011. The data quality and representativeness of cancer registries have gradually improved. Cancer registries have an irreplaceable role in research on cancer prevention and control. The disease burden of cancer is increasing, and the health department must implement effective measures to contain the increased cancer burden in China.

Entities:  

Mesh:

Year:  2015        PMID: 26370301      PMCID: PMC4593358          DOI: 10.1186/s40880-015-0042-6

Source DB:  PubMed          Journal:  Chin J Cancer        ISSN: 1944-446X


Introduction

Cancer is a major public health issue in China. It is the second leading cause of death, and its incidence and mortality continue to increase [1-3]. In 2008, the National Cancer Registration Program was launched by the Ministry of Health of China. Since then, the National Central Cancer Registry (NCCR) of China annually publishes cancer statistics based on the data reported by the cancer registries [4]. In this study, we analyzed the cancer incidence and mortality in cancer registration areas in 2011 and estimated the national numbers of new cancer cases and deaths to provide an overview of the current cancer statistics using data collected from local registries. The updated cancer burden results can be broadly used by the government, researchers, and clinicians for policy-making and research.

Methods

Data collection

A total of 234 cancer registries, located in 32 provinces, autonomous regions, and municipalities directly under the central government, submitted records of cancer new cases and deaths in 2011 to the NCCR. All data were evaluated based on the criteria of data quality of the NCCR. A total of 177 registries with qualified data were included in the final database for cancer statistics analysis in 2011. The registries identified new cancer cases from all hospitals, community health centers, medical insurance databases, and death registries (for cases only identified by death certification). The registries obtained information on cancer deaths from the death surveillance system, which collects death information from hospitals and the Civil Administration Bureau with available cremation records. Population information was collected from local statistical bureaus or household registry departments in local public security bureaus.

Data quality control

The proportion of cases with morphologic verification (MV%), percentage of cancer cases identified by death certification only (DCO%), mortality to incidence (M/I) ratio, percentage of uncertified cancers (UB%), and percentage of cancers with undefined or unknown primary sites (secondary) (O&U%) were used to evaluate the completeness, validity, and reliability of the cancer statistics.

Statistical analysis

Pooled data were stratified by area (urban and rural), sex (males and females), age group (0, 1–4, 5–9, …, 80–84, 85 years old and above), and cancer type. Cancer incident cases and deaths were estimated using age-specific rates, which were stratified by area, region (eastern, middle, western), cancer type, sex, and age. The 10 most common cancers in different groups were determined, and their proportions and cumulative rates were also calculated. The Chinese population census in 2000 and Segi’s population were used to determine age-standardized rates (ASRs) of incidence and mortality.

Results

Data sources

The 177 included cancer registries (77 in urban areas and 100 in rural areas) covered a total of 175,310,169 persons (98,341,507 in urban areas and 76,968,662 in rural areas). The overall indicators of MV%, DCO%, and M/I ratio were 70.14%, 2.44%, and 0.63, respectively. They were 72.92%, 2.17%, and 0.61 in urban registries and 65.34%, 2.90%, and 0.67 in rural registries, respectively.

Incidences of all cancers

In 2011, 3,372,175 new cancer cases were estimated. The crude incidence in the Chinese cancer registration areas was 250.28/1,00,000 (277.77/1,00,000 for males and 221.37/1,00,000 for females), and the ASRs of incidence by the Chinese standard population (ASRIC) and by the world standard population (ASRIW) were 186.34/1,00,000 and 182.76/1,00,000, respectively, with a cumulative incidence (0–74 years old) of 21.20%. The crude incidence and ASRIC were 261.38/1,00,000 and 189.89/1,00,000 in urban areas and 238.60/1,00,000 and 182.10/1,00,000 in rural areas, respectively (Table 1). Cancer incidence was relatively lower in persons before age 39, increased dramatically after age 40, peaked after age 80, and then slightly decreased after age 85. This pattern was similar between urban and rural areas.
Table 1

Cancer incidence in China in 2011

AreasSexCancer casesCrude incidence (1/105)ASRIC (1/105)ASRIW (1/105)Cumulative rate (%)
AllBoth3,372,175250.28186.34182.7621.20
Male1,918,533277.77213.66212.1825.02
Female1,453,642221.37161.47155.8417.43
UrbanBoth1,805,624261.38189.89185.7521.28
Male993,675281.81211.88210.1024.52
Female811,949240.09170.79164.3518.22
RuralBoth1,566,551238.60182.10179.2421.08
Male924,858273.57215.54214.3825.55
Female641,693201.49150.57146.0216.51

ASRIC age-standardized rate of incidence by the Chinese standard population in 2000, ASRIW age-standardized rate of incidence by the Segi’s world standard population.

Cancer incidence in China in 2011 ASRIC age-standardized rate of incidence by the Chinese standard population in 2000, ASRIW age-standardized rate of incidence by the Segi’s world standard population.

Mortalities of all cancers

It was estimated that 2,113,048 persons died of cancer in 2011. The crude mortality in Chinese cancer registration areas was 156.83/1,00,000 (194.88/1,00,000 for males and 116.81/1,00,000 for females), and the ASRs of mortality by the Chinese standard population (ASRMC) and by the world standard population (ASRMW) were 112.88/1,00,000 and 111.82/1,00,000, respectively, with a cumulative incidence of 12.69%. The crude mortality and ASRMC were 154.37/1,00,000 and 108.20/1,00,000 in urban areas and 159.42/1,00,000 and 117.97/1,00,000 in rural areas, respectively (Table 2). The cancer mortality was relatively lower in persons before age 45 and then dramatically increased, reaching its peak after age 85. The mortality in rural areas was the highest in the age 80–84 group. The age-specific mortality of males was lower in urban areas than in rural areas in most age groups before age 80.
Table 2

Cancer mortality in China in 2011

AreasSexDeathsCrude mortality (1/105)ASRMC (1/105)ASRMW (1/105)Cumulative rate (%)
AllBoth2,113,048156.83112.88111.8212.69
Male1,345,998194.88148.28147.4416.72
Female767,050116.8179.4278.318.67
UrbanBoth1,066,408154.37108.20107.1411.79
Male671,063190.31141.00140.3615.53
Female395,345116.9077.4276.148.15
RuralBoth1,046,640159.42117.97116.8413.65
Male674,935199.64156.03154.8317.98
Female371,705116.7181.6680.719.22

ASRMC age-standardized rate of mortality by the Chinese standard population in 2000, ASRMW age-standardized rate of mortality by the Segi’s world standard population.

Cancer mortality in China in 2011 ASRMC age-standardized rate of mortality by the Chinese standard population in 2000, ASRMW age-standardized rate of mortality by the Segi’s world standard population.

The 10 most common cancers in China

Lung cancer was the most common cancer in all areas, followed by female breast, gastric, liver, and colorectal cancers, with estimated new cases of 651,053, 248,620, 420,489, 355,595, and 310,244 in 2011, respectively. Lung cancer was the most frequently diagnosed cancer in males, followed by gastric, liver, esophageal, and colorectal cancers; breast cancer was the most common cancer in females, followed by lung, colorectal, gastric, and liver cancers (Table 3). The 10 most common cancers accounted for approximately 75% of all cancer cases (Figure 1). In urban areas, lung cancer was the most frequently diagnosed cancer (3,41,543 estimated new cases with an incidence of 49.44/1,00,000), followed by female breast, colorectal, gastric, and liver cancer; in rural areas, lung cancer was the most frequently diagnosed cancer (3,09,510 estimated new cases with an incidence of 47.14/1,00,000), followed by gastric, esophageal, liver, and colorectal cancers (Figures 2, 3).
Table 3

Ten cancers with the highest incidences in China, 2011

RankMalesFemales
SiteCasesIncidence (1/105)Proportion (%)ASRIC (1/105)SiteCasesIncidence (1/105)Proportion (%)ASRIC (1/105)
1Lung441,36463.9023.0148.44Breast248,62037.8617.1028.51
2Stomach296,41942.9215.4532.62Lung209,68931.9314.4321.93
3Liver264,63538.3213.7929.30Colorectum131,84020.089.0714.02
4Esophagus205,56029.7610.7122.47Stomach124,07018.898.5413.21
5Colorectum178,40425.839.3019.70Liver90,96013.856.269.64
6Bladder53,0747.682.775.82Cervix87,98213.406.0510.40
7Prostate49,0077.102.555.33Esophagus85,67813.055.898.85
8Pancreas45,3856.572.374.99Thyroid67,78810.324.668.70
9Brain, CNS43,2896.272.265.22Uterus57,7098.793.976.46
10Lymphoma41,2985.982.154.80Ovary45,2336.893.115.35

CNS central nervous system. Other abbreviations as in Table 1.

Figure 1

Ten cancers with the highest incidences in urban areas of China, 2011.

Figure 2

Cancer incidences and mortalities in urban and rural areas for males in China, 2011 (1/1,00,000).

Figure 3

Cancer incidences and mortalities in urban and rural areas for females in China, 2011 (1/1,00,000).

Ten cancers with the highest incidences in China, 2011 CNS central nervous system. Other abbreviations as in Table 1. Ten cancers with the highest incidences in urban areas of China, 2011. Cancer incidences and mortalities in urban and rural areas for males in China, 2011 (1/1,00,000). Cancer incidences and mortalities in urban and rural areas for females in China, 2011 (1/1,00,000). Lung cancer was the leading cause of death in China, followed by liver, gastric, esophageal, and colorectal cancers, with estimated deaths of 529,153, 322,417, 297,496, 218,957, and 149,722, respectively. In males, lung cancer was the leading cause of death, followed by liver, gastric, esophageal, and colorectal cancers; in females, lung cancer was also the leading cause of death, followed by gastric, liver, esophageal, and colorectal cancers (Table 4). The top 10 leading causes of cancer death accounted for approximately 80% of all cancer deaths (Figure 4).
Table 4

Ten cancers with the highest mortalities in China, 2011

RankMalesFemales
SiteDeathsMortality (1/105)Proportion (%)ASRMC (1/105)SiteDeathsMortality (1/105)Proportion (%)ASRMC (1/105)
1Lung364,43252.7627.0839.94Lung164,72125.0821.4716.68
2Liver239,21834.6417.7726.38Stomach90,79213.8311.849.21
3Stomach206,70429.9315.3622.69Liver83,19912.6710.858.61
4Esophagus154,58722.3811.4816.86Esophagus64,3719.808.396.38
5Colorectum86,42712.516.429.40Colorectum63,2959.648.256.26
6Pancreas40,5805.883.014.43Breast60,4739.217.886.57
7Brain, CNS28,5424.132.123.35Pancreas32,1434.894.193.21
8Leukemia27,9074.042.073.46Cervix23,3753.563.052.59
9Lymphoma25,0663.631.862.84Brain, CNS22,2343.392.902.54
10Bladder20,9493.031.562.23Leukemia19,7083.002.572.45

Abbreviations as in Tables 2 and 3.

Figure 4

Ten cancers with the highest mortalities in urban areas of China, 2011.

Ten cancers with the highest mortalities in China, 2011 Abbreviations as in Tables 2 and 3. Ten cancers with the highest mortalities in urban areas of China, 2011. The cancer patterns were different between urban and rural areas and between males and females. The main cancers in rural areas were gastric and esophageal cancers, followed by lung, liver, and colorectal cancers, whereas the main cancer in urban areas was lung cancer, followed by liver, gastric, and colorectal cancers.

Discussion

In 2014, there were 234 registries in China that submitted cancer registry data to the NCCR. The registered populations covered 16.4% of the Chinese population. Through double evaluations of data quality at the provincial and national levels, 177 registries were qualified for inclusion in the final pooled database, which was used for the evaluation of cancer statistics in 2011. For the cancer statistics in 2010, the national population obtained by the sixth Population Census, which only examined the residential population, was used for the cancer statistics estimations [4]. However, the household population is considered more suitable for this analysis because cancer data are based on household registration. The estimates of cancer incident cases and cancer deaths reasonably increased compared to those in previous years [5, 6], probably because of the aging population and the increasing trends of cancer incidence and mortality. Urban areas in China had a higher cancer incidence and lower cancer mortality than rural areas, and the cancer patterns were quite different between urban and rural areas [2, 3]. A recent study showed that these differences were decreased [7, 8]. Lung cancer is now the most common cancer in rural areas instead of gastric cancer, and this may be due to the high prevalence of tobacco smoking [9] and air pollution [10]. Liver cancer is still one of the most common cancers and one of the leading causes of cancer death in China [11, 12]. A current study showed that rural China had a lower 5-year relative survival rate than urban China [13, 14]. This disparity may be due to limited medical resources, the low number of cancer care centers and the greater number of patients with late-stage cancers in rural areas. The government should be aware of the differences in cancer statistics between urban and rural areas and implement effective measures to bridge the gap. In 2014, extra funds were provided to the national program to enhance follow-up and survival analyses, which are still lacking in most registries. The registration data should become more valuable and play an important role in cancer control. The National Cancer Center just started a Cancer Atlas Project, which will provide useful information about the geographic distribution of cancers to allow the National Cancer Control Program to be more efficient.
  12 in total

1.  Factors associated with smoking cessation among Chinese adults in rural China.

Authors:  Tingzhong Yang; Abu Saleh M Abdullah; Jabed Mustafa; Bin Chen; Xiaozhao Yang; Xiangxian Feng
Journal:  Am J Health Behav       Date:  2009 Mar-Apr

2.  [Analysis of liver cancer mortality in the national retrospective sampling survey of death causes in China, 2004 - 2005].

Authors:  Jian-guo Chen; Si-wei Zhang; Wan-qing Chen
Journal:  Zhonghua Yu Fang Yi Xue Za Zhi       Date:  2010-05

3.  Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2).

Authors:  Claudia Allemani; Hannah K Weir; Helena Carreira; Rhea Harewood; Devon Spika; Xiao-Si Wang; Finian Bannon; Jane V Ahn; Christopher J Johnson; Audrey Bonaventure; Rafael Marcos-Gragera; Charles Stiller; Gulnar Azevedo e Silva; Wan-Qing Chen; Olufemi J Ogunbiyi; Bernard Rachet; Matthew J Soeberg; Hui You; Tomohiro Matsuda; Magdalena Bielska-Lasota; Hans Storm; Thomas C Tucker; Michel P Coleman
Journal:  Lancet       Date:  2014-11-26       Impact factor: 79.321

4.  Annual report on status of cancer in China, 2010.

Authors:  Wanqing Chen; Rongshou Zheng; Siwei Zhang; Ping Zhao; Hongmei Zeng; Xiaonong Zou; Jie He
Journal:  Chin J Cancer Res       Date:  2014-02       Impact factor: 5.087

5.  [Trend analysis and projection of cancer incidence in China between 1989 and 2008].

Authors:  Wan-qing Chen; Rong-shou Zheng; Hong-mei Zeng; Si-wei Zhang; Ping Zhao; Jie He
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2012-07

6.  Liver cancer incidence and mortality in China, 2009.

Authors:  Wan-Qing Chen; Rong-Shou Zheng; Si-Wei Zhang
Journal:  Chin J Cancer       Date:  2013-03-15

7.  The incidences and mortalities of major cancers in China, 2009.

Authors:  Wanqing Chen; Rongshou Zheng; Siwei Zhang; Ping Zhao; Guanglin Li; Lingyou Wu; Jie He
Journal:  Chin J Cancer       Date:  2013-03

8.  Incidence and mortality of liver cancer in China, 2010.

Authors:  Kuang-Rong Wei; Xia Yu; Rong-Shou Zheng; Xia-Biao Peng; Si-Wei Zhang; Ming-Fang Ji; Zhi-Heng Liang; Zhi-Xiong Ou; Wan-Qing Chen
Journal:  Chin J Cancer       Date:  2014-07-11

9.  The incidences and mortalities of major cancers in China, 2010.

Authors:  Wan-Qing Chen; Rong-Shou Zheng; Si-Wei Zhang; Hong-Mei Zeng; Xiao-Nong Zou
Journal:  Chin J Cancer       Date:  2014-07-11

10.  Cancer survival in China, 2003-2005: a population-based study.

Authors:  Hongmei Zeng; Rongshou Zheng; Yuming Guo; Siwei Zhang; Xiaonong Zou; Ning Wang; Limei Zhang; Jingao Tang; Jianguo Chen; Kuangrong Wei; Suqin Huang; Jian Wang; Liang Yu; Deli Zhao; Guohui Song; Jianshun Chen; Yongzhou Shen; Xiaoping Yang; Xiaoping Gu; Feng Jin; Qilong Li; Yanhua Li; Hengming Ge; Fengdong Zhu; Jianmei Dong; Guoping Guo; Ming Wu; Lingbin Du; Xibin Sun; Yutong He; Michel P Coleman; Peter Baade; Wanqing Chen; Xue Qin Yu
Journal:  Int J Cancer       Date:  2014-10-03       Impact factor: 7.396

View more
  133 in total

1.  Study of natural IgG antibodies against vascular endothelial growth factor receptor 1 in hepatocellular carcinoma.

Authors:  Yilai Wang; Zhaoping Yan; Yile Huang; Cailing Qiu; Xiangyun Chen; Ying Hu; Qingyong Meng; Jun Wei
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

2.  HHLA2 overexpression is a novel biomarker of malignant status and poor prognosis in gastric cancer.

Authors:  Li Wei; Liang Tang; Haiyan Chang; Song Huo; Yan Li
Journal:  Hum Cell       Date:  2019-09-24       Impact factor: 4.174

3.  [Role of miRNA-340 in modulating gastric cancer cell proliferation and bioinformatic analysis].

Authors:  Jian Wang; Wenjing Chen; Huijuan Lin; Jiangyu Zhang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-07-30

4.  Effects and mechanisms of action of SARI on androgen-independent prostate cancer (DU145) cells.

Authors:  Qian Chen; Yonghong Gu; Shengwang Zhang; Hao Deng
Journal:  Tumour Biol       Date:  2016-10-14

5.  Overexpression of long non-coding RNA H19 is associated with unfavorable prognosis in patients with colorectal cancer and increased proliferation and migration in colon cancer cells.

Authors:  Shan-Wen Chen; Jing Zhu; Ju Ma; Jun-Ling Zhang; Shuai Zuo; Guo-Wei Chen; Xin Wang; Yi-Sheng Pan; Yu-Cun Liu; Peng-Yuan Wang
Journal:  Oncol Lett       Date:  2017-06-15       Impact factor: 2.967

6.  MicroRNA-34c-3p promotes cell proliferation and invasion in hepatocellular carcinoma by regulation of NCKAP1 expression.

Authors:  Cheng-Zuo Xiao; Wei Wei; Zhi-Xing Guo; Mei-Yin Zhang; Yong-Fa Zhang; Jia-Hong Wang; Ming Shi; Hui-Yun Wang; Rong-Ping Guo
Journal:  J Cancer Res Clin Oncol       Date:  2016-10-04       Impact factor: 4.553

7.  Identification of a prognostic 5-Gene expression signature for gastric cancer.

Authors:  Jun-Yi Hou; Yu-Gang Wang; Shi-Jie Ma; Bing-Yin Yang; Qian-Ping Li
Journal:  J Cancer Res Clin Oncol       Date:  2016-12-29       Impact factor: 4.553

8.  Overexpression of GRK6 associates with the progression and prognosis of colorectal carcinoma.

Authors:  Ran Tao; Qiang Li; Xiaofei Gao; Lilin Ma
Journal:  Oncol Lett       Date:  2018-02-12       Impact factor: 2.967

9.  Association of HER2 status with prognosis in gastric cancer patients undergoing R0 resection: A large-scale multicenter study in China.

Authors:  Guo-Shuang Shen; Jiu-Da Zhao; Jun-Hui Zhao; Xin-Fu Ma; Feng Du; Jie Kan; Fa-Xiang Ji; Fei Ma; Fang-Chao Zheng; Zi-Yi Wang; Bing-He Xu
Journal:  World J Gastroenterol       Date:  2016-06-21       Impact factor: 5.742

10.  Notch-1 signaling activates NF-κB in human breast carcinoma MDA-MB-231 cells via PP2A-dependent AKT pathway.

Authors:  Li Li; Jing Zhang; Niya Xiong; Shun Li; Yu Chen; Hong Yang; Chunhui Wu; Hongjuan Zeng; Yiyao Liu
Journal:  Med Oncol       Date:  2016-03-05       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.